Early Cancer Detection Platform
Multiple Solid Tumors
Pre-clinicalPlatform R&D
Key Facts
About Astrin Biosciences
Astrin Biosciences is pioneering a novel diagnostic platform designed to detect cancer in its earliest stages by monitoring real-time biological activity. The company's mission is to shift cancer diagnosis from reactive to proactive, enabling earlier intervention and better survival rates. While still in the development phase, their technology holds significant promise for improving screening paradigms across multiple cancer types. Astrin is positioned as a private, pre-revenue company focused on advancing its platform through research and development.
View full company profileTherapeutic Areas
Other Multiple Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| BAY 1817080 | Bayer | Phase 1 |
| Zanzalintinib + nivolumab | Exelixis | Phase 1b/2 |
| Zanzalintinib + atezolizumab | Exelixis | Phase 1b/2 |
| XL309 | Exelixis | Phase 1 |
| XB010 | Exelixis | Phase 1 |
| XB628 | Exelixis | Phase 1 |
| XB371 | Exelixis | Phase 1 |
| ADU-1805 | Exelixis | Phase 1 |
| Multiple Preclinical Programs | Perspective Therapeutics | Preclinical |
| Pre-Targeting Platform | Perspective Therapeutics | Preclinical |
| VDC Platform | Aura Biosciences | Pre-clinical/Discovery |
| MGC026 | MacroGenics | Phase 1 |